Zoryl 1 Tablet contains Glimepiride 1 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions primarily by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with inadequate response to diet and exercise alone. Glimepiride enhances peripheral insulin sensitivity, facilitating increased glucose uptake in muscle and adipose tissue, contributing to overall blood glucose reduction. Zoryl 1 is typically prescribed as part of a comprehensive diabetes management plan, including diet modification, physical activity, and regular monitoring of blood glucose levels. The medication is administered once daily, preferably with breakfast or the first main meal, to minimize the risk of hypoglycemia. Common adverse effects may include hypoglycemia, weight gain, gastrointestinal disturbances, and allergic skin reactions. Caution is advised in patients with hepatic or renal impairment, and it should be used carefully in elderly patients due to increased susceptibility to hypoglycemia. Regular monitoring of blood glucose and periodic assessment of renal and hepatic function are recommended during therapy. Zoryl 1 should not be used in type 1 diabetes or diabetic ketoacidosis. Consultation with a healthcare professional is essential before initiating treatment to ensure appropriate dosing and to minimize potential risks.